Nature Communications (Jul 2021)
Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma
- Luuk van Hooren,
- Alessandra Vaccaro,
- Mohanraj Ramachandran,
- Konstantinos Vazaios,
- Sylwia Libard,
- Tiarne van de Walle,
- Maria Georganaki,
- Hua Huang,
- Ilkka Pietilä,
- Joey Lau,
- Maria H. Ulvmar,
- Mikael C. I. Karlsson,
- Maria Zetterling,
- Sara M. Mangsbo,
- Asgeir S. Jakola,
- Thomas Olsson Bontell,
- Anja Smits,
- Magnus Essand,
- Anna Dimberg
Affiliations
- Luuk van Hooren
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University
- Alessandra Vaccaro
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University
- Mohanraj Ramachandran
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University
- Konstantinos Vazaios
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University
- Sylwia Libard
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University
- Tiarne van de Walle
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University
- Maria Georganaki
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University
- Hua Huang
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University
- Ilkka Pietilä
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University
- Joey Lau
- Department of Medical Cell Biology, Uppsala University
- Maria H. Ulvmar
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University
- Mikael C. I. Karlsson
- Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet
- Maria Zetterling
- Department of Neuroscience, Neurology, Uppsala University
- Sara M. Mangsbo
- Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University
- Asgeir S. Jakola
- Department of Neurosurgery, Sahlgrenska University Hospital
- Thomas Olsson Bontell
- Department of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg
- Anja Smits
- Department of Neuroscience, Neurology, Uppsala University
- Magnus Essand
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University
- Anna Dimberg
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala University
- DOI
- https://doi.org/10.1038/s41467-021-24347-7
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 14
Abstract
Agonistic CD40 antibodies (αCD40) have broad immunostimulatory properties, however their efficacy in glioma remains unclear. Here the authors show that αCD40 promotes the formation of tertiary lymphoid structures but does not improve survival and impairs the response to immune checkpoint blockade in murine glioma models.
